Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CBZ Clear all
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

NCT06596668
View directory record Official record
Conditions
Healthy
Interventions
bomedemstat, carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 17, 2026, 9:55 PM EDT
Not listed Phase 4 Interventional

Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder

NCT00325286
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Plus Extended- Release Carbamazepine
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 14, 2007 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

NCT06633419
View directory record Official record
Conditions
Healthy
Interventions
Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

NCT06348888
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Itraconazole, Carbamazepine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 17, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

Photosensitivity Proof of Concept Trial

NCT00894010
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
carbamazepine 400mg, levetiracetam 1000mg
Drug
Lead sponsor
The Epilepsy Study Consortium
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 17, 2026, 9:55 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine

NCT01097720
View directory record Official record
Conditions
Autism, Developmental Delay, Birth Defects
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
36 Months to 83 Months
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 17, 2026, 9:55 PM EDT
Completed No phase listed Observational Results available

Pathogenesis of Adverse Drug Reactions

NCT00224952
View directory record Official record
Conditions
Seizures
Interventions
No intervention; Urine Collection
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 16 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Louisville, Kentucky • Kansas City, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

NCT00610571
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

NCT01465997
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
Not listed
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Alabaster, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

NCT01128959
View directory record Official record
Conditions
Epilepsy
Interventions
Intravenous Carbamazepine (IV CBZ)
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Torrance, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional Results available

Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

NCT02214615
View directory record Official record
Conditions
Erythromelalgia
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

Drug Therapy for Alcohol Detoxification

NCT00000441
View directory record Official record
Conditions
Alcoholism
Interventions
lorazepam (Ativan), carbamazepine (Tegretol)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

NCT00612638
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar, O6-BG, and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

The Young Adult and Pediatric Bipolar Study

NCT00350857
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Extended-Release Carbamazepine
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

Carbamazepine Extended-Release for the Treatment of Bipolar Depression

NCT00203567
View directory record Official record
Conditions
Bipolar Depression
Interventions
carbamazepine ER
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 24, 2008 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine, Carbamazepine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers

NCT00006395
View directory record Official record
Conditions
Healthy
Interventions
St. John's Wort
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

NCT06893081
View directory record Official record
Conditions
Healthy
Interventions
MK-8527, CBZ
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 17, 2026, 9:55 PM EDT
Completed Phase 4 Interventional

Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181870
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
carbamazepine ER (Equetro)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 17, 2026, 9:55 PM EDT